The regulation of oncogenic Ras/ERK signalling by dual-specificity mitogen activated protein kinase phosphatases (MKPs)
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Dual-specificity MAP kinase (MAPK) phosphatases (MKPs or DUSPs) are well-established negative regulators of MAPK signalling in mammalian cells and tissues. By virtue of their differential subcellular localisation and ability to specifically recognise, dephosphorylate and inactivate different MAPK isoforms, they are key spatiotemporal regulators of pathway activity. Furthermore, as they are transcriptionally regulated as downstream targets of MAPK signalling they can either act as classical negative feedback regulators or mediate cross talk between distinct MAPK pathways. Because MAPKs and particularly Ras/ERK signalling are implicated in cancer initiation and development, the observation that MKPs are abnormally regulated in human tumours has been interpreted as evidence that these enzymes can either suppress or promote carcinogenesis. However, definitive evidence of such roles has been lacking. Here we review recent work based on the use of mouse models, biochemical studies and clinical data that demonstrate key roles for MKPs in modulating the oncogenic potential of Ras/ERK signalling and also indicate that these enzymes may play a role in the response of tumours to certain anticancer drugs. Overall, this work reinforces the importance of negative regulatory mechanisms in modulating the activity of oncogenic MAPK signalling and indicates that MKPs may provide novel targets for therapeutic intervention in cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S.-I., Watanabe, H., Kurashina, K., Hatanaka, H., et al. (2007) · Nature · doi:10.1038/nature05945 · Cited by 5,439
Differential regulation of MAP kinase signalling by dual-specificity protein phosphatases
Owens, D. M., & Keyse, S. M. (2007) · Oncogene · doi:10.1038/sj.onc.1210412 · Cited by 777
Self-citationHaigis, K. M., Kendall, K. R., Wang, Y., Cheung, A., Haigis, M. C., Glickman, J. N., Niwa-Kawakita, M., Sweet-Cordero, A., Sebolt-Leopold, J., Shannon, K. M., et al. (2008) · Nature Genetics · doi:10.1038/ng.115 · Cited by 610
Dual‐specificity MAP kinase phosphatases (MKPs): Shaping the outcome of MAP kinase signalling
Caunt, C. J., & Keyse, S. M. (2013) · The FEBS Journal · doi:10.1111/j.1742-4658.2012.08716.x · Cited by 535
Self-citationA negative feedback signaling network underlies oncogene-induced senescence
Courtois-Cox, S., Genther Williams, S. M., Reczek, E. E., Johnson, B. W., McGillicuddy, L. T., Johannessen, C. M., Hollstein, P. E., MacCollin, M., & Cichowski, K. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.10.003 · Cited by 501
Identification of mutant K-Ras-dependent phenotypes using a panel of isogenic cell lines
Vartanian, S., Bentley, C., Brauer, M. J., Li, L., Shirasawa, S., Sasazuki, T., Kim, J.-S., Haverty, P., Stawiski, E., Modrusan, Z., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.394130 · Cited by 65
Research works printed but not linked: 49
- Theodosiou, 2002, MAP kinase phosphatases, Genome Biol., 3, 10.1186/gb-2002-3-7-reviews3009 · DOI
- Camps, 2000, Dual specificity phosphatases: a gene family for control of MAP kinase function, FASEB J., 14, 6, 10.1096/fasebj.14.1.6 · DOI · Paper page
- Keyse, 2000, Protein phosphatases and the regulation of mitogen-activated protein kinase signalling, Curr. Opin. Cell Biol., 12, 186, 10.1016/S0955-0674(99)00075-7 · DOI · Paper page
- Camps, 1998, Catalytic activation of the phosphatase MKP-3 by ERK2 mitogen-activated protein kinase, Science, 280, 1262, 10.1126/science.280.5367.1262 · DOI · Paper page
- Stewart, 1999, Crystal structure of the MAPK phosphatase Pyst1 catalytic domain and implications for regulated activation, Nat. Struct. Biol., 6, 174, 10.1038/5861 · DOI
- Pratilas, 2009, (V600E)BRAF is associated with disabled feedback inhibition of RAF–MEK signaling and elevated transcriptional output of the pathway, Proc. Natl. Acad. Sci. U. S. A., 106, 4519, 10.1073/pnas.0900780106 · DOI · Paper page
- Keyse, 2008, Dual-specificity MAP kinase phosphatases (MKPs) and cancer, Cancer Metastasis Rev., 27, 253, 10.1007/s10555-008-9123-1 · DOI · Paper page
- Nunes-Xavier, 2011, Dual-specificity MAP kinase phosphatases as targets of cancer treatment, Anticancer Agents Med. Chem., 11, 109, 10.2174/187152011794941190 · DOI
- Groom, 1996, Differential regulation of the MAP, SAP and RK/p38 kinases by Pyst1, a novel cytosolic dual-specificity phosphatase, EMBO J., 15, 3621, 10.1002/j.1460-2075.1996.tb00731.x · DOI · Paper page
- Muda, 1996, MKP-3, a novel cytosolic protein–tyrosine phosphatase that exemplifies a new class of mitogen-activated protein kinase phosphatase, J. Biol. Chem., 271, 4319, 10.1074/jbc.271.8.4319 · DOI · Paper page
- Karlsson, 2004, Both nuclear-cytoplasmic shuttling of the dual specificity phosphatase MKP-3 and its ability to anchor MAP kinase in the cytoplasm are mediated by a conserved nuclear export signal, J. Biol. Chem., 279, 41882, 10.1074/jbc.M406720200 · DOI · Paper page
- Eblaghie, 2003, Negative feedback regulation of FGF signaling levels by Pyst1/MKP3 in chick embryos, Curr. Biol., 13, 1009, 10.1016/S0960-9822(03)00381-6 · DOI · Paper page
- Li, 2007, DUSP6 (MKP3) is a negative feedback regulator of FGF-stimulated ERK signaling during mouse development, Development, 134, 167, 10.1242/dev.02701 · DOI · Paper page
- Ekerot, 2008, Negative-feedback regulation of FGF signalling by DUSP6/MKP-3 is driven by ERK1/2 and mediated by Ets factor binding to a conserved site within the DUSP6/MKP-3 gene promoter, Biochem. J., 412, 287, 10.1042/BJ20071512 · DOI · Paper page
- Zhang, 2010, Dual specificity phosphatase 6 (DUSP6) is an ETS-regulated negative feedback mediator of oncogenic ERK signaling in lung cancer cells, Carcinogenesis, 31, 577, 10.1093/carcin/bgq020 · DOI · Paper page
- Packer, 2009, Identification of direct transcriptional targets of (V600E)BRAF/MEK signalling in melanoma, Pigment Cell Melanoma Res., 22, 785, 10.1111/j.1755-148X.2009.00618.x · DOI · Paper page
- Furukawa, 2003, Potential tumor suppressive pathway involving DUSP6/MKP-3 in pancreatic cancer, Am. J. Pathol., 162, 1807, 10.1016/S0002-9440(10)64315-5 · DOI · Paper page
- Xu, 2005, Abrogation of DUSP6 by hypermethylation in human pancreatic cancer, J. Hum. Genet., 50, 159, 10.1007/s10038-005-0235-y · DOI
- Furukawa, 2005, Distinct progression pathways involving the dysfunction of DUSP6/MKP-3 in pancreatic intraepithelial neoplasia and intraductal papillary–mucinous neoplasms of the pancreas, Mod. Pathol., 18, 1034, 10.1038/modpathol.3800383 · DOI
- Okudela, 2009, Down-regulation of DUSP6 expression in lung cancer: its mechanism and potential role in carcinogenesis, Am. J. Pathol., 175, 867, 10.2353/ajpath.2009.080489 · DOI
- Marchetti, 2004, Inducible expression of a MAP kinase phosphatase-3-GFP chimera specifically blunts fibroblast growth and Ras-dependent tumor formation in nude mice, J. Cell. Physiol., 199, 441, 10.1002/jcp.10465 · DOI
- Brunet, 1999, Nuclear translocation of p42/p44 mitogen-activated protein kinase is required for growth factor-induced gene expression and cell cycle entry, EMBO J., 18, 664, 10.1093/emboj/18.3.664 · DOI · Paper page
- Albeck, 2013, Frequency-modulated pulses of ERK activity transmit quantitative proliferation signals, Mol. Cell, 49, 249, 10.1016/j.molcel.2012.11.002 · DOI · Paper page
- Messina, 2011, Dual-specificity phosphatase DUSP6 has tumor-promoting properties in human glioblastomas, Oncogene, 30, 3813, 10.1038/onc.2011.99 · DOI
- Li, 2012, Increased levels of DUSP6 phosphatase stimulate tumourigenesis in a molecularly distinct melanoma subtype, Pigment Cell Melanoma Res., 25, 188, 10.1111/j.1755-148X.2011.00949.x · DOI
- Degl’Innocenti, 2013, DUSP6/MKP3 is overexpressed in papillary and poorly differentiated thyroid carcinoma and contributes to neoplastic properties of thyroid cancer cells, Endocr. Relat. Cancer, 20, 23, 10.1530/ERC-12-0078 · DOI
- Shojaee, 2015, Erk negative feedback control enables pre-B cell transformation and represents a therapeutic target in acute lymphoblastic leukemia, Cancer Cell, 28, 114, 10.1016/j.ccell.2015.05.008 · DOI · Paper page
- Molina, 2009, Zebrafish chemical screening reveals an inhibitor of Dusp6 that expands cardiac cell lineages, Nat. Chem. Biol., 5, 680, 10.1038/nchembio.190 · DOI · Paper page
- Maillet, 2008, DUSP6 (MKP3) null mice show enhanced ERK1/2 phosphorylation at baseline and increased myocyte proliferation in the heart affecting disease susceptibility, J. Biol. Chem., 283, 31246, 10.1074/jbc.M806085200 · DOI · Paper page
- Korotchenko, 2014, In vivo structure–activity relationship studies support allosteric targeting of a dual specificity phosphatase, ChemBioChem, 15, 1436, 10.1002/cbic.201402000 · DOI
- Mandl, 2005, Specific inactivation and nuclear anchoring of extracellular signal-regulated kinase 2 by the inducible dual-specificity protein phosphatase DUSP5, Mol. Cell. Biol., 25, 1830, 10.1128/MCB.25.5.1830-1845.2005 · DOI · Paper page
- Kucharska, 2009, Regulation of the inducible nuclear dual-specificity phosphatase DUSP5 by ERK MAPK, Cell. Signal., 21, 1794, 10.1016/j.cellsig.2009.07.015 · DOI
- Shin, 2013, Down-regulation of dual-specificity phosphatase 5 in gastric cancer by promoter CpG island hypermethylation and its potential role in carcinogenesis, Am. J. Pathol., 182, 1275, 10.1016/j.ajpath.2013.01.004 · DOI
- Cai, 2015, Down-regulation of dual-specificity phosphatase 5 predicts poor prognosis of patients with prostate cancer, Int. J. Clin. Exp. Med., 8, 4186
- Rushworth, 2014, Dual-specificity phosphatase 5 regulates nuclear ERK activity and suppresses skin cancer by inhibiting mutant Harvey-Ras (HRasQ61L)-driven SerpinB2 expression, Proc. Natl. Acad. Sci. U. S. A., 111, 18267, 10.1073/pnas.1420159112 · DOI · Paper page
- Zhou, 2001, Overexpression of plasminogen activator inhibitor type 2 in basal keratinocytes enhances papilloma formation in transgenic mice, Cancer Res., 61, 970
- Croucher, 2008, Revisiting the biological roles of PAI2 (SerpinB2) in cancer, Nat. Rev. Cancer, 8, 535, 10.1038/nrc2400 · DOI · Paper page
- Holmes, 2015, DUSP5 negatively regulates IL-33-mediated eosinophil survival and function, EMBO J., 34, 218, 10.15252/embj.201489456 · DOI
- Slack, 2001, Distinct binding determinants for ERK2/p38alpha and JNK map kinases mediate catalytic activation and substrate selectivity of map kinase phosphatase-1, J. Biol. Chem., 276, 16491, 10.1074/jbc.M010966200 · DOI · Paper page
- Lampaki, 2015, Defining the role of tyrosine kinase inhibitors in early stage non-small cell lung cancer, J. Cancer, 6, 568, 10.7150/jca.11893 · DOI
- Russo, 2015, A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): old successes and future perspectives, Oncotarget, 6, 26814, 10.18632/oncotarget.4254 · DOI · Paper page
- Tan, 2015, Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer, Lancet Oncol., 16, e447, 10.1016/S1470-2045(15)00246-6 · DOI · Paper page
- Phuchareon, 2015, EGFR inhibition evokes innate drug resistance in lung cancer cells by preventing Akt activity and thus inactivating Ets-1 function, Proc. Natl. Acad. Sci. U. S. A., 112, E3855, 10.1073/pnas.1510733112 · DOI · Paper page
- Donepudi, 2008, c-Src trafficking and co-localization with the EGF receptor promotes EGF ligand-independent EGF receptor activation and signaling, Cell. Signal., 20, 1359, 10.1016/j.cellsig.2008.03.007 · DOI
- Awad, 2014, ALK inhibitors in non-small cell lung cancer: crizotinib and beyond, Clin. Adv. Hematol. Oncol., 12, 429
- Hrustanovic, 2015, RAS–MAPK dependence underlies a rational polytherapy strategy in EML4–ALK-positive lung cancer, Nat. Med., 21, 1038, 10.1038/nm.3930 · DOI · Paper page
- Lai, 2014, Dynamic reprogramming of signaling upon met inhibition reveals a mechanism of drug resistance in gastric cancer, Sci. Signal., 7, ra38, 10.1126/scisignal.2004839 · DOI
- Chan, 2008, Loss of MKP3 mediated by oxidative stress enhances tumorigenicity and chemoresistance of ovarian cancer cells, Carcinogenesis, 29, 1742, 10.1093/carcin/bgn167 · DOI · Paper page
- Barr, 2010, Protein tyrosine phosphatases as drug targets: strategies and challenges of inhibitor development, Future Med. Chem., 2, 1563, 10.4155/fmc.10.241 · DOI · Paper page
Cited by
Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies
Bahar, M. E., Kim, H. J., & Kim, D. R. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01705-z · Cited by 888
“377,378 ERK-mediated feedback regulation directly targets RAF proteins, reducing dimerization.”
BackgroundVertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition
Ryan, M. B., Fece de la Cruz, F., Phat, S., Myers, D. T., Wong, E., Shahzade, H. A., Hong, C. B., & Corcoran, R. B. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3523 · Cited by 496
“Because our in vitro data suggest that SHP2 inhibition can abrogate adaptive feedback reactivation of RAS pathway signaling following KRAS inhibition, we evaluated the degree of RAS–MAPK pathway inhibition in tumors after 4 days of each treatment by assessing transcript levels of ERK transcriptional targets (30, 31).”
MethodSignal pathways of melanoma and targeted therapy
Guo, W., Wang, H., & Li, C. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00827-6 · Cited by 379
MAPK/ERK Signaling Pathway in Hepatocellular Carcinoma
Moon, H., & Ro, S. W. (2021) · Cancers · doi:10.3390/cancers13123026 · Cited by 326
The role of wild type RAS isoforms in cancer
Zhou, B., Der, C. J., & Cox, A. D. (2016) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2016.07.012 · Cited by 130
Metadata
- Authors
- Kidger, A. M., & Keyse, S. M.
- Venue
- Seminars in Cell & Developmental Biology
- Publisher
- Elsevier BV
- Published
- 2016-02
- Volume
- 50
- Pages
- 125-132
- ISSN
- 1084-9521 (ISSN-L)
- OpenAlex
- W2239096611
- Cited by
- 222
- References
- 6
- FWCI
- 14.14
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.